Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial.

Détails

Ressource 1Télécharger: REF.pdf (159.58 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_63978C9C55C1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial.
Périodique
The Journal of antimicrobial chemotherapy
Auteur⸱e⸱s
Pagani J.L., Chave J.P., Casjka C., Glauser M.P., Bille J.
ISSN
0305-7453 (Print)
ISSN-L
0305-7453
Statut éditorial
Publié
Date de publication
08/2002
Peer-reviewed
Oui
Volume
50
Numéro
2
Pages
231-240
Langue
anglais
Notes
Publication types: Clinical Trial ; Comparative Study ; Journal Article ; Randomized Controlled Trial
Publication Status: ppublish
Résumé
Over 37 months, we conducted a prospective double-blind, randomized study in a cohort of 138 HIV-infected patients to compare the effect of two different strategies on the prevention and treatment of oropharyngeal candidiasis relapses and on the development of clinical and microbiological resistance to fluconazole. Each episode was treated with a 7 day course of fluconazole 200 mg/day, followed by secondary prophylaxis with fluconazole 150 mg once weekly matched to placebo. The duration of the double-blind phase of the study, from the day of randomization to the first primary end-point, was 347 +/- 186 days for the fluconazole group and 196 +/- 128 days for the placebo group (P < 0.001). A total of 33 patients remained relapse-free during the course of the study. Clinical failure was observed in a total of five patients (four in the fluconazole group, one in the placebo group; P = 0.15). Microbiological resistance was recorded in 12 patients (eight in the fluconazole group, four in the placebo group; P = 0.20). There were no significant treatment group differences in microbiological resistance whether comparisons were made for all cases or for cases up to 1 month post-study. In the few patients who developed clinical and/or microbiological resistance, the cumulative dose of fluconazole before entry into the study was a mean value of 8.6 g (compared with 2.9 g in patients without clinical and/or microbiological resistance). In summary, patients treated with secondary prophylaxis suffered fewer relapses of oropharyngeal candidiasis. Development of resistant candidiasis (clinical and/or microbiological) was rarely seen in either group and its incidence was not significantly different.

Mots-clé
AIDS-Related Opportunistic Infections/prevention & control, Adult, Candidiasis, Oral/prevention & control, Double-Blind Method, Drug Resistance, Fungal, Fluconazole/adverse effects, Fluconazole/pharmacology, Fluconazole/therapeutic use, HIV Seropositivity/drug therapy, Humans, Male, Patients, Prospective Studies, Secondary Prevention
Pubmed
Open Access
Oui
Création de la notice
11/02/2008 13:39
Dernière modification de la notice
14/02/2022 8:55
Données d'usage